How Wegovy affects the heart: what the trial evidence shows

What the SELECT trial actually found, and why it matters for heart health

Most weight-loss medicines have been neutral on cardiovascular outcomes at best. SELECT changed that picture. Running across 45 countries and enrolling 17,604 adults with a BMI of 27 or above and a history of cardiovascular disease but no diabetes, the trial followed participants for an average of around 33 months. Those receiving semaglutide 2.4 mg weekly were 20% less likely to experience a major cardiovascular event (defined as non-fatal heart attack, non-fatal stroke, or death from cardiovascular causes) than those on placebo, both groups receiving standard care throughout. That absolute difference translated to roughly 1.5 fewer events per 100 patients over three years.

The mechanism is not fully pinned down. Weight loss alone likely accounts for part of it. GLP-1 receptors are also present in cardiac tissue, and researchers believe direct cardioprotective signalling plays a role, separate from what the scales show. The MHRA took this evidence seriously: Wegovy now carries a specific UK authorisation for cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease. If you want to understand whether Wegovy affects your heart and what the evidence really means for patients, that question is covered in depth elsewhere on this site. You can also read more about how semaglutide interacts with the cardiovascular system in depth elsewhere on this site.

One thing SELECT did not study was people without existing heart disease. The cardiovascular indication is specific; it does not extend to general heart-health maintenance, and clinical teams assess eligibility case by case. If your interest is weight management rather than cardiovascular risk reduction, the weight-management licence applies on its own terms, BMI thresholds, comorbidities, diet and activity support.

Heart rate on Wegovy: what the data show and when to mention it to a clinician

A distinct and more common question is whether Wegovy raises heart rate. It does, modestly, in some people. Across semaglutide trials the average increase in resting heart rate was around one to four beats per minute, small, generally transient, and in most participants clinically unremarkable. The mechanism appears to relate to GLP-1 receptor activity in cardiac conduction tissue rather than to weight change or fluid shifts.

For most people this is a numbers-on-paper finding rather than a felt symptom. A smaller group notices palpitations, particularly in the first few weeks or after a dose increase. These tend to settle as the body adjusts. Sustained or worsening palpitations, chest tightness, or any symptoms that feel significant should be discussed with a clinician promptly rather than waited out.

People with pre-existing arrhythmias or on rate-controlling medicines are not automatically excluded from treatment, but those factors form part of the prescriber's assessment. If you have had an ablation, carry a defibrillator, or take a beta-blocker specifically for rhythm control, your prescriber needs the full picture before making any recommendation. Our page on Wegovy and heart rate covers the physiology in more detail for anyone who wants to go deeper.

Blood pressure, weight loss, and the broader cardiovascular picture

Beyond the SELECT headline, the cardiovascular effects of semaglutide extend into blood pressure, lipid profiles, and inflammation markers. STEP 1 (the core 68-week phase-3 weight-management trial) reported meaningful reductions in systolic blood pressure (around 6 mmHg on average) and improvements in triglycerides and HDL cholesterol alongside weight reduction. These are clinically relevant for people whose cardiovascular risk is driven by metabolic syndrome rather than overt heart disease.

Blood pressure changes can have practical implications for people already on antihypertensives. As weight falls and blood pressure improves, existing doses may need adjusting, something to flag at any review appointment rather than manage independently. The same logic applies to statins and other cardiac medicines: improving cardiometabolic markers is the aim, but doing so while on multiple agents needs coordinated clinical oversight.

Wegovy's effects on the liver are a related part of the metabolic story; how semaglutide affects liver health is worth reading if you have been told about fatty liver disease or raised liver enzymes. For a full overview of the treatment and how it fits into a weight-management plan, the Wegovy treatment page covers eligibility, how the dose escalates, and what to expect.

Getting a proper assessment before starting

The cardiovascular evidence for semaglutide is genuinely encouraging. It is also genuinely complex, heart rate effects, blood pressure dynamics, interaction with existing cardiac medicines, and eligibility for the cardiovascular indication all require a clinician's eye. No published trial result substitutes for someone reviewing your ECG history, your current prescription list, and your specific risk profile.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. That review happens the same day, your answers do not sit in an automated queue. Orders placed before 12pm on a working day, once clinically approved, are dispatched the same day and delivered free the next working day by DPD in plain packaging. The prescriber checks medical history, current medicines, and whether Wegovy is appropriate for your situation. If it is, treatment begins promptly; if not, you will be told why. You can also read about how our clinical team works if you want reassurance before starting.

The cost question comes up early for most people. Understanding what Wegovy actually costs through legitimate UK channels helps set realistic expectations, because price varies significantly by provider and dose. When you are ready to take the next step, check your eligibility and start a free consultation, no obligation, and the clinical review is included.